YMMUNO BIOTECH
A Biotech start-up focused on developing new science-based products. Immunotherapies and Orally passive immunization is our cup of tea. Nowadays we are working on a new therapy to improve life quality in Crohn´s Disease patients and improving a new methodology to reduce the use of antibiotics in hospitalized elderly patients.
YMMUNO BIOTECH
Social Links:
Industry:
Biotechnology Dietary Supplements Pharmaceutical
Founded:
2019-02-05
Address:
Florianópolis, Santa Catarina, Brazil
Country:
Brazil
Website Url:
http://www.ymmuno.com
Total Employee:
1+
Status:
Active
Contact:
+5548999187299
Email Addresses:
[email protected]
Total Funding:
60 K BRL
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Amazon SSL By Default GoDaddy DNS AWS Global Accelerator OpenResty GoDaddy SSL Google Adsense
Similar Organizations
Aquit
Aquit develops preventive treatments for infections in fish that replace antibiotics, improve survival rates, and boost natural immunity.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Zhiyi Pharmaceutics
Zhiyi Pharmaceutics focuses on the research and development of second-generation probiotics and Live Biotherapeutics.
Current Employees Featured
Founder
Investors List
FAPESC - Fundação de Amparo à Pesquisa e Inovação
FAPESC - Fundação de Amparo à Pesquisa e Inovação investment in Seed Round - Ymmuno Biotech
Official Site Inspections
http://www.ymmuno.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ymmuno Biotech"
HOME | Ymmunobio
At Ymmunobio, our research is based on our deep understanding of immuno-oncology and precision cancer treatments. We leverage our profound knowledge of biologics, focusing on …See details»
Ymmuno Biotech - Crunchbase Company Profile & Funding
Ymmuno Biotech closed its last funding round on Aug 14, 2020 from a Seed round. Who are Ymmuno Biotech 's competitors? Alternatives and possible competitors to Ymmuno Biotech …See details»
ABOUT US | Ymmunobio
Ymmunobio is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed. Dr. Katrin Rupalla & Dr. Peter Schiemann co-founded Ymmunobio in …See details»
Ymmunobio - LinkedIn
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies.See details»
Ymmunobio - Crunchbase Company Profile & Funding
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments. It makes extensive progress in developing antibodies that have an …See details»
Ymmunobio AG - Swiss Biotech
Https://www.ymmuno.bio â€+41 76 378 59 30; Send an email; Dr. Peter Schiemann, CEO & Chairman of the Board; Some insights. ... Type of organization. Private company. Year of …See details»
CONTACT - Ymmunobio
We want to hear from you. Please use the contact form and follow us on LinkedIn to keep with the Ymmunobio news!See details»
Ymmuno Biotech - Funding, Financials, Valuation & Investors
Using IgY as an oral immunotherapy for infectious disease, focused in research and development to reduce antibiotics resistanceSee details»
Ymmunobio at the Swiss Biotech Day
Www.ymmuno.bio: Speaker: Dr. Peter Schiemann, CEO & Chairman: Company profile. Ymmunobio was founded in 2021 focusing on GI cancers with our lead indication of gastric …See details»
Ymmunobio - BIO International Convention 2025
Ymmunobio is a pre-clinical stage Biotech company focusing on first in class solid tumor treatments. Their novel target has superior properties (highest prevalence, large presence and …See details»
Ymmunobio secures $1.4M seed funding - startupticker.ch
Nov 14, 2023 Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies …See details»
Ymmunobio: The Venture Leader Biotech developing on first-in …
May 13, 2024 Meet Peter Schiemann, CEO of Ymmunobio. The Biotech startup is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed. …See details»
Ymmunobio Accepted into Innosuisse Core Coaching
Mar 8, 2023 Participation in the international program guides startups in creating and developing business traction RIEHEN, SWITZERLAND, March 8, 2023 ─ Ymmunobio, a preclinical stage …See details»
Ymmunobio AG - startup.ch
Ymmunobio AG: Ymmunobio has identified a new tumor marker with superior properties: 1. It is present in at least 13 solid tumors 2. It has a prevalence of up to 98% in cancer patients 3. It is …See details»
ImmUnity Canada - Primary Immunodeficiency Society
Formerly the Canadian Immunodeficiencies Patient Organization. Empowering people with primary immunodeficiency to live well. Learn More. Newly diagnosed? Start here. Find support …See details»
Ymmuno Biotech - Contacts, Employees, Board Members
Using IgY as an oral immunotherapy for infectious disease, focused in research and development to reduce antibiotics resistanceSee details»
Synergistic Integration of Immune Regulation and Bioactive …
1 day ago Peripheral nerve injury presents a significant clinical challenge due to the limited regenerative capacity of the injured nerves, often resulting in permanent functional deficits. A …See details»
OUR PLATFORM - Ymmunobio
The scientists of Ymmunobio are innovating cancer treatment with novel therapeutic antibodies. Our novel CEACAM1 antibody not only acts as a checkpoint inhibitor but also as an immune …See details»
Imprint Labs Announces $15M in Funding to Decode the Immune
5 days ago Imprint Labs is a forensic immunology Focused Research Organization (FRO) building experimental and machine learning tools to identify the hidden causes of and cures for …See details»
NEWS - Ymmunobio
RIEHEN, Switzerland, April 18, 2025 /PRNewswire/ -- Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to the development of new cancer therapeutics, is proud to …See details»